openPR Logo
Press release

Alzheimers Disease Therapeutics Market Projected to Witness a Double-Digit CAGR During 2010-2020

01-04-2018 12:35 PM CET | Health & Medicine

Press release from: Persistence Market Research

Alzheimers Disease Therapeutics Market Projected to Witness

Alzheimer’s disease is a neurodegenerative, progressive, non-reversible disorder. Alzheimer’s disease is caused due to abnormal functioning of brain cells i.e. failure of synaptic transmission, resulting in the loss of cognitive functions. Some of the signs and symptoms of alzheimer’s disease are memory loss, insomnia, repetitive movements, agitation, anxiety, depression and loss of reasoning abilities. All memory and mental functioning may be lost in advanced stages of the disease. Alzheimer’s disease may lead to death. According to National Institute of Aging, Alzheimer’s disease is the common form of dementia.

Request Report for TOC @ https://www.persistencemarketresearch.com/toc/3401

North America dominates the global market for alzheimer’s disease therapeutics due to large number of aging population. Asia followed by the Europe are expected to show high growth rates in the next five years in the global alzheimer’s disease therapeutics market. China and India are expected to be the fastest growing alzheimer’s disease therapeutics markets in Asia-Pacific region. Some of the key driving forces for alzheimer’s disease therapeutics market in emerging countries are increasing R&D investment, large pool of patients and improvement of healthcare infrastructure.

Request To Sample of Report @ https://www.persistencemarketresearch.com/samples/3401

In recent times there is increased in use of alzheimer’s disease therapeutics due to increasing prevalence of alzheimer’s disease. Increase geriatric population, increase in healthcare expenditure and increased government funding are some of the key factors driving the growth for the global alzheimer’s disease therapeutics market. In addition, increasing healthcare awareness and new diagnostic technologies for alzheimer’s disease are also fuelling the growth of the global alzheimer’s disease therapeutics market. However, strict regulations and long approval time for alzheimer’s disease therapeutics and expiry of several patent drugs are some of the major factors restraining the growth for the global alzheimer’s disease patient market.

Increasing R&D investment of biopharmaceutical companies would lead to growth in alzheimer’s disease therapeutics market in Asia. In addition, innovation of new drugs to treat, slow and prevent alzheimers disease and early diagnosis of alzheimers disease would develop opportunities for the global alzheimer’s disease therapeutics market. Some of the major companies operating in the global alzheimer’s disease patient market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer, Inc., Novartis AG., Eisai Co., Ltd., Actavis, Daiichi Sankyo, Transtech Pharma and H. Lundbeck A/S.

Pre Book Full Report @ https://www.persistencemarketresearch.com/checkout/3401

About Us

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us

Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA,Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Alzheimers Disease Therapeutics Market Projected to Witness a Double-Digit CAGR During 2010-2020 here

News-ID: 885180 • Views:

More Releases from Persistence Market Research

Artificial Intelligence as a Service Market Forecasted to Grow at 34.6% CAGR, Reaching USD 82.4 Billion by 2031
Artificial Intelligence as a Service Market Forecasted to Grow at 34.6% CAGR, Re …
The Artificial Intelligence as a Service (AIaaS) market has emerged as one of the most transformative segments in the global technology ecosystem. By providing AI capabilities on a subscription or pay-per-use model, AIaaS allows organizations to deploy advanced AI functionalities without the need for significant in-house infrastructure. This model has democratized access to AI, enabling small and medium-sized enterprises to leverage predictive analytics, natural language processing, and machine learning tools
Server Operating System Market Anticipated to Witness Robust Growth, Reaching USD 34.5 Billion by 2031
Server Operating System Market Anticipated to Witness Robust Growth, Reaching US …
The server operating system market is witnessing robust growth, driven by the rapid expansion of data centers and the surging adoption of cloud technologies across enterprises worldwide. Server operating systems form the backbone of modern IT infrastructure, enabling organizations to efficiently manage hardware resources, deploy applications, and maintain high levels of system reliability and security. As businesses increasingly migrate to cloud environments and data-intensive operations grow, demand for powerful, scalable,
Manufacturing Operations Management Software Industry Anticipated to Witness Rapid Growth, Reaching USD 69.8 Billion by 2032
Manufacturing Operations Management Software Industry Anticipated to Witness Rap …
The Manufacturing Operations Management (MOM) software market is rapidly emerging as a cornerstone of digital transformation in the manufacturing sector. As industries increasingly adopt Industry 4.0 practices, the need for advanced solutions that integrate production planning, real-time monitoring, quality control, and process optimization has surged. MOM software enables manufacturers to streamline operations, reduce production downtime, and improve overall efficiency, making it an indispensable tool across automotive, pharmaceutical, aerospace, and consumer
G.Fast Chipset Market Forecast to Expand with Absolute $ Growth of USD 28.3 Billion by 2032
G.Fast Chipset Market Forecast to Expand with Absolute $ Growth of USD 28.3 Bill …
The G.Fast chipset market has emerged as a pivotal segment within the broadband and telecommunication infrastructure industry, driven by the rising demand for high-speed internet and improved last-mile connectivity solutions. With advancements in fiber-to-the-distribution-point (FTTdp) networks, the adoption of G.Fast chipsets has witnessed unprecedented growth across residential, commercial, and industrial applications. These chipsets enable ultra-fast broadband speeds over existing copper lines, bridging the performance gap between fiber and legacy infrastructures,

All 5 Releases


More Releases for Alzheimer’s

Europe Alzheimer’s Drug Pipeline Analysis
The incidence of Alzheimer’s disease has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been observed that close to 50% of dependency of aged people in Europe is attributed for by Alzheimer’s disease. The rapid growth in the prevalence of Alzheimer's disease over the next few decades in Europe is expected to result in immense pressure
Media Advisory: Alzheimer’s Disease Resource Center, Inc. Presents 10th Annual …
Who: Mary Ann Malack-Ragona, Executive Director/Chief Executive Officer, Alzheimer’s Disease Resource Center, Inc. (ADRC) Participating Walk for Alzheimer’s teams and individuals Mickey B, Radio Personality, WGBB Radio and Master of Ceremonies Ronald McDonald The Liberty Bells, USO troupe What: Alzheimer’s Disease Resource Center, Inc. (ADRC) is presenting its 10th Annual Old Bethpage Walk for Alzheimer’s & Mexican Fiesta. There will be an opening ceremony with Mickey B, Radio Personality, WGBB Radio, as the Master of
Home Care Assistance Partners with the Alzheimer’s Association to Promote Earl …
(Palo Alto, CA – November 29, 2011) Home Care Assistance, North America’s leading provider of in-home care for seniors, announced today that, along with companies including Genworth, Starbucks, Intel and Pfizer, they are now a Champion Partner of the Alzheimer’s Early Detection Alliance (AEDA). The AEDA is a program renowned for raising Alzheimer’s awareness and promoting early detection of the disease. As a member of this important alliance, Home
Alzheimer’s Association Long Island Announces Release of Latest Report on Alzh …
Alzheimer’s Association Long Island announced the release of the most recent report about Alzheimer’s disease. “Alzheimer’s from the Frontlines: Challenges a National Alzheimer’s Plan Must Address” provides a look into the unrelenting challenges brought on by this disease by offering insights and perspectives from individuals across the country who participated in the Alzheimer’s Association’s public input process. The Association and over 70 of its chapters hosted 132 input sessions throughout
Otava Alzheimer’s Disease Targeted Libraries
Alzheimer’s disease (AD) is a devastating and always fatal neurodegenerative disorder characterized by progressive impairment of cognitive function and emotional disturbances. Currently, more than 25 million people worldwide live with AD. But there is no cure for AD and no treatment to reverse its progression, there are medicines available that can help treat symptoms in some people with this disease. Intensive scientific research around the world brings us closer to
Alzheimer’s Association Long Island Presents Public Input Session for National …
On August 24, Alzheimer’s Association Long Island will hold a public input session to solicit views, comments and perspectives from stakeholders in the Alzheimer’s community to assist in the development of a successful National Alzheimer’s Plan. The recommendations and comments expressed during these input sessions, taking place across the country in August, will be collected and shared this fall with officials from the U.S. Department of Health and Human Services,